Mesenchymal Stem Cell Therapy for Type 2 Diabetes: Synergistic β-Cell Regeneration, Immune Modulation, and Exosome-Mediated Glucose Homeostasis.
Fuente:
PubMed
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Format: | Artículo científico |
| Sprache: | en |
| Veröffentlicht: |
Stem cells international
2026
|
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1868266037069217792 |
|---|---|
| author | Yang, Jia Chen, Yinglong Jing, Huanmei Liu, Chang Chen, Xiaoling Chu, Jiaju Chen, Liyun Tang, Shijie Yu, Fei Zhang, Wancong |
| author_facet | Yang, Jia Chen, Yinglong Jing, Huanmei Liu, Chang Chen, Xiaoling Chu, Jiaju Chen, Liyun Tang, Shijie Yu, Fei Zhang, Wancong Yang, Jia Chen, Yinglong Jing, Huanmei Liu, Chang Chen, Xiaoling Chu, Jiaju Chen, Liyun Tang, Shijie Yu, Fei Zhang, Wancong |
| collection | PubMed - marine biology |
| contents | Mesenchymal Stem Cell Therapy for Type 2 Diabetes: Synergistic β-Cell Regeneration, Immune Modulation, and Exosome-Mediated Glucose Homeostasis. Yang, Jia Chen, Yinglong Jing, Huanmei Liu, Chang Chen, Xiaoling Chu, Jiaju Chen, Liyun Tang, Shijie Yu, Fei Zhang, Wancong Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia, insulin resistance, and a progressive decline in pancreatic β-cell function, leading to impaired glucose regulation. It is often accompanied by severe complications, including cardiovascular diseases, nephropathy, and retinopathy. Conventional treatments, such as sulfonylurea pills, insulin injections, and GLP-1 receptor agonist injections, provide transient glycemic control but are often costly with unstable efficacy and long-term side effects. Pancreatic islet transplantation, while effective in some cases, is limited by donor scarcity, graft rejection, and the need for lifelong immunosuppression. Recently, mesenchymal stem cells (MSCs) have emerged as a promising alternative due to their multipotent differentiation potential, immunomodulatory properties, and regenerative capabilities. This review examines the therapeutic roles of MSCs in β-cell regeneration, inflammation modulation, and tissue repair while also addressing key challenges in clinical translation. However, given the lack of long-term clinical data, the conclusions presented remain preliminary and should be interpreted with caution. This article, therefore, aims to provide a foundational reference for future research, rather than definitive clinical guidance. |
| format | Artículo científico |
| id | pubmed_42292743 |
| institution | PubMed |
| language | en |
| publishDate | 2026 |
| publisher | Stem cells international |
| record_format | pubmed |
| spellingShingle | Mesenchymal Stem Cell Therapy for Type 2 Diabetes: Synergistic β-Cell Regeneration, Immune Modulation, and Exosome-Mediated Glucose Homeostasis. Yang, Jia Chen, Yinglong Jing, Huanmei Liu, Chang Chen, Xiaoling Chu, Jiaju Chen, Liyun Tang, Shijie Yu, Fei Zhang, Wancong Mesenchymal Stem Cell Therapy for Type 2 Diabetes: Synergistic β-Cell Regeneration, Immune Modulation, and Exosome-Mediated Glucose Homeostasis. Yang, Jia Chen, Yinglong Jing, Huanmei Liu, Chang Chen, Xiaoling Chu, Jiaju Chen, Liyun Tang, Shijie Yu, Fei Zhang, Wancong Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia, insulin resistance, and a progressive decline in pancreatic β-cell function, leading to impaired glucose regulation. It is often accompanied by severe complications, including cardiovascular diseases, nephropathy, and retinopathy. Conventional treatments, such as sulfonylurea pills, insulin injections, and GLP-1 receptor agonist injections, provide transient glycemic control but are often costly with unstable efficacy and long-term side effects. Pancreatic islet transplantation, while effective in some cases, is limited by donor scarcity, graft rejection, and the need for lifelong immunosuppression. Recently, mesenchymal stem cells (MSCs) have emerged as a promising alternative due to their multipotent differentiation potential, immunomodulatory properties, and regenerative capabilities. This review examines the therapeutic roles of MSCs in β-cell regeneration, inflammation modulation, and tissue repair while also addressing key challenges in clinical translation. However, given the lack of long-term clinical data, the conclusions presented remain preliminary and should be interpreted with caution. This article, therefore, aims to provide a foundational reference for future research, rather than definitive clinical guidance. |
| title | Mesenchymal Stem Cell Therapy for Type 2 Diabetes: Synergistic β-Cell Regeneration, Immune Modulation, and Exosome-Mediated Glucose Homeostasis. |
| url | https://pubmed.ncbi.nlm.nih.gov/42292743/ |